Overview

Symptom Adapted Therapy in GERD Patients

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether a maintenance treatment over 12 weeks with esomeprazole 20 mg daily will sufficiently give control over GERD symptoms and how it compares either with an on-demand therapy with esomeprazole 20 mg or an as needed therapy (wait and see regimen) with rescue medication only (antacid), following a 4-weeks acute treatment phase with either esomeprazole 20 mg or esomeprazole 40 mg.
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Aluminum Hydroxide
Esomeprazole
Magnesium trisilicate